$29.09 0.00 (0.00%)

National Bankshares Inc/VA (NKSH)

National Bankshares Inc. (NKSH) is a regional banking company headquartered in Virginia. It provides a range of financial services including personal and commercial banking, lending, and investment services through its community-focused approach. The company emphasizes personalized customer service and operates primarily within Virginia and surrounding regions.

Dividend Yield 5.19%
Payout Frequency

Dividend History

Pay DateAmountEx-DateRecord Date
June 2, 2025$0.732025-05-272025-05-27
December 2, 2024$0.782024-11-252024-11-25
June 3, 2024$0.732024-05-242024-05-28
December 1, 2023$0.782023-11-172023-11-20
June 1, 2023$0.732023-05-192023-05-22

Dividends Summary

Company News

Long Bonds: Breakout Above July Highs Set to Stoke Recession Fears - Investing.com
Investing.com • Michele Schneider • July 23, 2024

The article discusses the potential breakout of long bonds above July highs, which could signal growing recession fears in the market.

National Bankshares, Inc. Completes Acquisition of Frontier Community Bank
GlobeNewswire Inc. • National Bankshares, Inc. • June 3, 2024

National Bankshares, Inc. (Nasdaq: NKSH) completed its acquisition of Frontier Community Bank effective June 1, 2024.

First Guaranty Bancshares (FGBI) Soars 10.6%: Is Further Upside Left in the Stock?
Zacks Investment Research • Zacks Equity Research • May 1, 2024

First Guaranty Bancshares (FGBI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023
Benzinga • Benzinga Insights • July 24, 2023

Upgrades Maxim Group upgraded the previous rating for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) from Hold to Buy. For the first quarter, Galmed Pharmaceuticals had an EPS of $1.09, compared to year-ago quarter EPS of $3.60. The stock has a 52-week-high of $14.18 and a 52-week-low of $1.10. At the end of the last trading period, Galmed Pharmaceutic...